
USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$20.74B
Market Cap
30.18
P/E Ratio
4.47
EPS
$153.06
52 Week High
$68.70
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $2.9B |
| Total Revenue | $4.4B |
| Cost Of Revenue | $1.5B |
| Costof Goods And Services Sold | $1.5B |
| Operating Income | -$833M |
| Selling General And Administrative | $1.1B |
| Research And Development | $1.2B |
| Operating Expenses | $3.7B |
| Investment Income Net | - |
| Net Interest Income | -$54M |
| Interest Income | $46M |
| Interest Expense | $100M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $354M |
| Income Before Tax | -$1.2B |
| Income Tax Expense | $44M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$1.2B |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$1.1B |
| Ebitda | -$725M |
| Net Income | -$1.2B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $2.9B |
| Total Revenue | $4.4B |
| Cost Of Revenue | $1.5B |
| Costof Goods And Services Sold | $1.5B |
| Operating Income | -$833M |
| Selling General And Administrative | $1.1B |
| Research And Development | $1.2B |
| Operating Expenses | $3.7B |
| Investment Income Net | - |
| Net Interest Income | -$54M |
| Interest Income | $46M |
| Interest Expense | $100M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $354M |
| Income Before Tax | -$1.2B |
| Income Tax Expense | $44M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$1.2B |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$1.1B |
| Ebitda | -$725M |
| Net Income | -$1.2B |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Illumina, Inc. is a leading global biotechnology company based in San Diego, California, specializing in genomic analysis technologies since its founding in 1998. Renowned for its innovative sequencing, genotyping, and gene expression solutions, Illumina serves a variety of markets, including research, clinical diagnostics, and agricultural genomics, thereby significantly contributing to the advancement of personalized medicine. The company is committed to transforming human health through ongoing innovation and has established a prominent position in the genomics landscape by enabling breakthroughs in genetic research and diagnostics.